Celsion (CLSN) Will Present Significant GEN-1 Combo Data in Ovarian Cancer at …

Celsion (CLSN) Will Present Significant GEN-1 Combo Data in Ovarian Cancer at …

The presentation will be held on Monday, April 18, 2016 (1:00 pm to 5:00 pm) and will summarize results from preclinical studies demonstrating significant synergistic anticancer effects when GEN-1 is combined with Avastin and Doxil, a current Standard

(Visited 5 times, 1 visits today)
9
Like
Save

Comments

Comments are disabled for this post.